NC
SYRE icon

NBW Capital’s Spyre Therapeutics SYRE Stock Holding History

NBW Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$291K Hold
19,430
– – 0.06% 82
2025
Q1 		$314K Hold
19,430
– – 0.07% 79
2024
Q4 		$452K Sell
19,430
-7,500
-28% -$220K 0.08% 78
2024
Q3 		$792K Sell
26,930
-7,430
-22% -$207K 0.15% 71
2024
Q2 		$808K Hold
34,360
– – 0.16% 74
2024
Q1 		$1.3M Buy
+34,360
New +$996K 0.27% 68

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

NBW Capital's SYRE Position: Q2 2025 in Review

NBW Capital held its Spyre Therapeutics (SYRE) position steady in Q2 2025 at 19,430 shares worth $291K. The position accounts for 0.06% of the portfolio, ranked #82.

NBW Capital first reported a position in SYRE in Q1 2024 and has held it in 6 quarters since. The position peaked at $1.3M in Q1 2024. 129 funds tracked by Wall St. Rank hold SYRE as of Q2 2025.

  • NBW Capital held 19,430 shares of Spyre Therapeutics worth $291K as of Q2 2025.
  • NBW Capital left its Spyre Therapeutics share count unchanged in Q2 2025.
  • Spyre Therapeutics made up 0.06% of NBW Capital's portfolio in Q2 2025, its #82 holding.
  • NBW Capital first reported a position in Spyre Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • NBW Capital's Spyre Therapeutics position peaked at $1.3M in Q1 2024.
  • 129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2025.

Based on NBW Capital's 13F filing for Q2 2025, filed 13 Aug 2025.